6938 Stock Chart & Stats
$50.60
$2.60(5.42%)
―
--
Day’s Range― - ―
52-Week Range$43.60 - $95.80
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
HK$8.04B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.65
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding170,554,920
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Suzhou Ribo Life Science Co., Ltd. Class H News
6938 FAQ
What was Suzhou Ribo Life Science Co., Ltd. Class H’s price range in the past 12 months?
Suzhou Ribo Life Science Co., Ltd. Class H lowest stock price was $43.60 and its highest was $95.80 in the past 12 months.
What is Suzhou Ribo Life Science Co., Ltd. Class H’s market cap?
Suzhou Ribo Life Science Co., Ltd. Class H’s market cap is HK$8.04B.
When is Suzhou Ribo Life Science Co., Ltd. Class H’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Suzhou Ribo Life Science Co., Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Suzhou Ribo Life Science Co., Ltd. Class H overvalued?
According to Wall Street analysts Suzhou Ribo Life Science Co., Ltd. Class H’s price is currently Undervalued.
Does Suzhou Ribo Life Science Co., Ltd. Class H pay dividends?
Suzhou Ribo Life Science Co., Ltd. Class H does not currently pay dividends.
What is Suzhou Ribo Life Science Co., Ltd. Class H’s EPS estimate?
Suzhou Ribo Life Science Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Suzhou Ribo Life Science Co., Ltd. Class H have?
Suzhou Ribo Life Science Co., Ltd. Class H has 170,554,920 shares outstanding.
What happened to Suzhou Ribo Life Science Co., Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Suzhou Ribo Life Science Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:6938
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Suzhou Ribo Life Science Co., Ltd. Class H
Suzhou Ribo Life Science Co., Ltd. researches and develops novel therapeutics for the treatment of cardiovascular, metabolic, renal, and liver diseases in Chinese mainland and internationally. It develops RBD4059, which is phase 2 clinical trial for treating thrombotic diseases; RBD5044 that is in phase 2 clinical trial for treating hypertrigly ceridemia; RBD7022, which is in phase 2 clinical trial for the treatment of hypercho lesterolemia; RBD7007 and RBD2080 that are in Phase I clinical trial for the treatment of renal diseases; and RBD1119 for treating thrombotic diseases that is in Phase I clinical trial. The company also develops SR122 and SR126 for treating dyslipidemia; RBD3103 for treating renal diseases; RBD6096 for the treatment of thrombotic diseases; SR118 for treating metabolic diseases; RBD1016, which is in Phase II clinical trial for the treatment of CHB and CHD; RBD3133 for treating weight loss; RBD8088 for treating glioma; SR131 for treating CNS diseases; and SR111, SR112, and SR113 for the treatment of metabolic dysfunction-associated steatohepatitis. Suzhou Ribo Life Science Co., Ltd. was incorporated in 2007 and is based in Kunshan, China.
Zai Lab Ltd
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Sirnaomics Ltd.
―
CStone Pharmaceuticals
―
Shanghai Henlius Biotech, Inc. Class H
―